- Home
- AIRS vs CCCC Comparison
AIRS vs CCCC Comparison
Compare AIRS & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIRS
- CCCC
- Stock Information
- Founded
- AIRS 2012
- CCCC 2015
- Country
- AIRS United States
- CCCC United States
- Employees
- AIRS N/A
- CCCC N/A
- Industry
- AIRS Medical/Nursing Services
- CCCC Biotechnology: Pharmaceutical Preparations
- Sector
- AIRS Health Care
- CCCC Health Care
- Exchange
- AIRS Nasdaq
- CCCC Nasdaq
- Market Cap
- AIRS 334.6M
- CCCC 396.0M
- IPO Year
- AIRS 2021
- CCCC 2020
- Fundamental
- Price
- AIRS $7.00
- CCCC $4.25
- Analyst Decision
- AIRS Hold
- CCCC Buy
- Analyst Count
- AIRS 3
- CCCC 6
- Target Price
- AIRS $5.50
- CCCC $10.00
- AVG Volume (30 Days)
- AIRS 227.4K
- CCCC 1.1M
- Earning Date
- AIRS 11-08-2024
- CCCC 10-31-2024
- Dividend Yield
- AIRS N/A
- CCCC N/A
- EPS Growth
- AIRS N/A
- CCCC N/A
- EPS
- AIRS N/A
- CCCC N/A
- Revenue
- AIRS $188,780,000.00
- CCCC $33,668,000.00
- Revenue This Year
- AIRS N/A
- CCCC $76.74
- Revenue Next Year
- AIRS $11.17
- CCCC N/A
- P/E Ratio
- AIRS N/A
- CCCC N/A
- Revenue Growth
- AIRS N/A
- CCCC 65.45
- 52 Week Low
- AIRS $2.92
- CCCC $1.06
- 52 Week High
- AIRS $9.20
- CCCC $11.88
- Technical
- Relative Strength Index (RSI)
- AIRS 55.11
- CCCC 33.20
- Support Level
- AIRS $5.54
- CCCC $3.84
- Resistance Level
- AIRS $9.20
- CCCC $6.20
- Average True Range (ATR)
- AIRS 0.71
- CCCC 0.44
- MACD
- AIRS -0.12
- CCCC -0.16
- Stochastic Oscillator
- AIRS 39.89
- CCCC 15.71
About AIRS AirSculpt Technologies Inc.
AirSculpt Technologies Inc is a national provider of body contouring procedures delivering a premium consumer experience under its brand Elite Body Sculpture. At Elite Body Sculpture, company provide custom body contouring using proprietary AirSculpt method that removes unwanted fat in a minimally invasive procedure.
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.